search
Back to results

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (JCXH-105)

Primary Purpose

Herpes Zoster (HZ), Shingles, Infectious Disease

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
JCXH-105
Active Control (Shingrix)
Sponsored by
Immorna Biotherapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Herpes Zoster (HZ) focused on measuring srRNA vaccine, Shingles vaccine, Herpes Zoster (HZ) vaccine, Healthy adult participants (aged 50 to 69 years)

Eligibility Criteria

50 Years - 69 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Sex: Male or female; female subjects may be of childbearing potential, of nonchildbearing potential, or postmenopausal. Age: 50 to 69 years of age, inclusive, at screening. Status: Healthy subjects. Note: Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease, in the opinion of the Investigator, following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead electrocardiogram (ECG) recording, hematology, blood chemistry, serology, and urinalysis. Healthy subjects may have stable pre-existing disease defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks prior to enrollment. Subjects must agree to not be vaccinated with any HZ vaccine while participating in this study. All values for hematology and clinical chemistry tests of blood and urine within the normal range OR showing no clinically relevant deviations based on medical history, considering stable pre-existing diseases (see Healthy Subjects above), as judged by the Investigator. Exclusion Criteria: Subjects with a history of HZ or current diagnosis of shingles. Previous vaccination against HZ. Subjects with any respiratory illness deemed clinically relevant by the Investigator within the past month OR hospitalization >24 hours for any reason within the past month prior to the first vaccine administration (JCXH-105 or Shingrix). Subjects with history of myocarditis or pericarditis, or with AEs after mRNA vaccination that are in nature and severity beyond the common expected AEs necessitating medical intervention. Subjects who have received an mRNA-based vaccine (e.g., Spikevax, Comirnaty, etc.) 30 days prior to Day 1. Subjects who received any non-live vaccine within 14 days prior to the first vaccine administration (JCXH-105 or Shingrix). Subjects who received within 28 days prior to first vaccine administration (JCXH-105 or Shingrix): (1) Any live vaccine, (2) Immunomodulators or immune-suppressive medication, (3) Granulocyte-macrophage colony-stimulating factor, (4) Three or more consecutive days of systemic corticosteroids. Note: subjects on stable-dose steroid replacement (for chronic disease such as iatrogenic deficiency) of prednisone ≤10 mg/day or equivalent are allowed, and (5) Other investigational agents or devices. Subjects with active or suspected immunosuppression, immunodeficiency, or autoimmune disease. Subjects receiving systemic antiviral therapy. Subjects with a positive screening test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or anti-human HIV-1 and 2 antibodies. Subjects with a positive screening test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Subjects with a known history of active or latent tuberculosis (bacillus tuberculosis).

Sites / Locations

  • CenExel RCARecruiting
  • CenExel FCRRecruiting
  • CenExel HRIRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Investigational Product

Active Control

Arm Description

Participants randomized to this arm will be given the investigational product (JCXH-105).

Participants randomized to this arm will be given the FDA approved Shingrix.

Outcomes

Primary Outcome Measures

SAE Frequency
Frequency of SAEs characterized by type, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration through follow-up completion
Injection site reaction
Solicited local injection site reactions characterized by frequency, severity, and duration recorded within 7 days after each vaccine administration (JCXH-105 or Shingrix)
Solicited systemic reaction frequency
Solicited systemic adverse reactions characterized by frequency, severity, and duration recorded within 7 days after each vaccine administration (JCXH-105 or Shingrix)
AE frequency
Adverse events (AEs) including unsolicited AEs, characterized by type, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration to within 30 days following each vaccine administration
Medically attended AE frequency
Medically attended AEs (MAAEs) characterized by frequency, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration (JCXH-105 or Shingrix) through follow-up completion
The frequency of potential immune-mediated adverse events"
Potential immune-mediated disease (pIMDs) characterized by frequency, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration (JCXH-105 or Shingrix) through follow-up completion

Secondary Outcome Measures

Cellular immunogenicity of the JCXH-105 and Shingrix vaccine
Frequency of glycoprotein E (gE)-specific CD4+ T cells expressing 2 or more markers of activation in peripheral blood mononuclear cells (PBMCs) analyzed with flow cytometry on Day 1 pre-dose (baseline) and Days 15, 31, 75, 91, and 241 (Follow-up visit)

Full Information

First Posted
May 3, 2023
Last Updated
May 23, 2023
Sponsor
Immorna Biotherapeutics, Inc.
Collaborators
ICON plc
search

1. Study Identification

Unique Protocol Identification Number
NCT05871541
Brief Title
A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Acronym
JCXH-105
Official Title
A Phase 1 Randomized, Double-Blinded, Active-Controlled, 2-Dose Study to Assess the Safety and Immunogenicity of a Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects 50 to 69 Years of Age.
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 2023 (Anticipated)
Primary Completion Date
February 23, 2024 (Anticipated)
Study Completion Date
March 21, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Immorna Biotherapeutics, Inc.
Collaborators
ICON plc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster) Participant will be randomized to receive either JCXH-105 or Shingrix.
Detailed Description
This Phase 1 study plans to enroll a total of 75 participants. Three cohorts with 3 different dose levels of JCXH-105 will be explored and each cohort will enroll 25 participants (20 randomized to JCXH-105 and 5 randomized to Shingrix) for a total of 75 participants. The dose level of JCXH-105 will depend on the time the participant joins the study. Each participant will receive two single intramuscular (IM) injections of study treatment (JCXH-105 or Shingrix) on day 1 and day 61 (±2 days on day 61)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Herpes Zoster (HZ), Shingles, Infectious Disease
Keywords
srRNA vaccine, Shingles vaccine, Herpes Zoster (HZ) vaccine, Healthy adult participants (aged 50 to 69 years)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Double blinded study
Allocation
Randomized
Enrollment
75 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Investigational Product
Arm Type
Experimental
Arm Description
Participants randomized to this arm will be given the investigational product (JCXH-105).
Arm Title
Active Control
Arm Type
Active Comparator
Arm Description
Participants randomized to this arm will be given the FDA approved Shingrix.
Intervention Type
Biological
Intervention Name(s)
JCXH-105
Intervention Description
As IM injection
Intervention Type
Biological
Intervention Name(s)
Active Control (Shingrix)
Intervention Description
As IM injection
Primary Outcome Measure Information:
Title
SAE Frequency
Description
Frequency of SAEs characterized by type, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration through follow-up completion
Time Frame
Day 1 - Day 241
Title
Injection site reaction
Description
Solicited local injection site reactions characterized by frequency, severity, and duration recorded within 7 days after each vaccine administration (JCXH-105 or Shingrix)
Time Frame
7 days after the first and second vaccination
Title
Solicited systemic reaction frequency
Description
Solicited systemic adverse reactions characterized by frequency, severity, and duration recorded within 7 days after each vaccine administration (JCXH-105 or Shingrix)
Time Frame
7 days after the first and second vaccination
Title
AE frequency
Description
Adverse events (AEs) including unsolicited AEs, characterized by type, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration to within 30 days following each vaccine administration
Time Frame
30 days after the first and second vaccination
Title
Medically attended AE frequency
Description
Medically attended AEs (MAAEs) characterized by frequency, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration (JCXH-105 or Shingrix) through follow-up completion
Time Frame
Day 1 - Day 241
Title
The frequency of potential immune-mediated adverse events"
Description
Potential immune-mediated disease (pIMDs) characterized by frequency, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration (JCXH-105 or Shingrix) through follow-up completion
Time Frame
Day 1 - Day 241
Secondary Outcome Measure Information:
Title
Cellular immunogenicity of the JCXH-105 and Shingrix vaccine
Description
Frequency of glycoprotein E (gE)-specific CD4+ T cells expressing 2 or more markers of activation in peripheral blood mononuclear cells (PBMCs) analyzed with flow cytometry on Day 1 pre-dose (baseline) and Days 15, 31, 75, 91, and 241 (Follow-up visit)
Time Frame
Day 1 - Day 241

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Sex: Male or female; female subjects may be of childbearing potential, of nonchildbearing potential, or postmenopausal. Age: 50 to 69 years of age, inclusive, at screening. Status: Healthy subjects. Note: Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease, in the opinion of the Investigator, following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead electrocardiogram (ECG) recording, hematology, blood chemistry, serology, and urinalysis. Healthy subjects may have stable pre-existing disease defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks prior to enrollment. Subjects must agree to not be vaccinated with any HZ vaccine while participating in this study. All values for hematology and clinical chemistry tests of blood and urine within the normal range OR showing no clinically relevant deviations based on medical history, considering stable pre-existing diseases (see Healthy Subjects above), as judged by the Investigator. Exclusion Criteria: Subjects with a history of HZ or current diagnosis of shingles. Previous vaccination against HZ. Subjects with any respiratory illness deemed clinically relevant by the Investigator within the past month OR hospitalization >24 hours for any reason within the past month prior to the first vaccine administration (JCXH-105 or Shingrix). Subjects with history of myocarditis or pericarditis, or with AEs after mRNA vaccination that are in nature and severity beyond the common expected AEs necessitating medical intervention. Subjects who have received an mRNA-based vaccine (e.g., Spikevax, Comirnaty, etc.) 30 days prior to Day 1. Subjects who received any non-live vaccine within 14 days prior to the first vaccine administration (JCXH-105 or Shingrix). Subjects who received within 28 days prior to first vaccine administration (JCXH-105 or Shingrix): (1) Any live vaccine, (2) Immunomodulators or immune-suppressive medication, (3) Granulocyte-macrophage colony-stimulating factor, (4) Three or more consecutive days of systemic corticosteroids. Note: subjects on stable-dose steroid replacement (for chronic disease such as iatrogenic deficiency) of prednisone ≤10 mg/day or equivalent are allowed, and (5) Other investigational agents or devices. Subjects with active or suspected immunosuppression, immunodeficiency, or autoimmune disease. Subjects receiving systemic antiviral therapy. Subjects with a positive screening test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or anti-human HIV-1 and 2 antibodies. Subjects with a positive screening test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Subjects with a known history of active or latent tuberculosis (bacillus tuberculosis).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Manpreet Khara
Phone
+1 913-574-6900
Email
Manpreet.Khara@iconplc.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer Ferrante
Facility Information:
Facility Name
CenExel RCA
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dayana Deltejo
Facility Name
CenExel FCR
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Gonzalez
Facility Name
CenExel HRI
City
Berlin
State/Province
New Jersey
ZIP/Postal Code
08009
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lindsay Moellers

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

We'll reach out to this number within 24 hrs